Skip to main content
Figure 4 | Molecular Cancer

Figure 4

From: Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

Figure 4

Reduction of p-S6 with the combination of dabrafenib and AKTi in BRAFV600mutated cell lines. Western blot analysis of the effects of dabrafenib, AKTi or the combination on MAPK and the PI3K-AKT pathway in six representative BRAFV600 mutated cell lines with differential sensitivity to single agent AKTi and dabrafenib (Table 2). The analysis was performed after 24 hours exposure to DMSO (control), dabrafenib (50 nM), AKTi (2.5 μM) or the combination.

Back to article page